Menu Search
Equities

Gubra A/S

GUBRA:CPH

Gubra A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)468.00
  • Today's Change-6.00 / -1.27%
  • Shares traded14.57k
  • 1 Year change+298.09%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Gubra A/S had net income fall from a gain of 4.31m to a loss of 44.52m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 19.25% to 23.13%.
Gross margin58.74%
Net profit margin-20.79%
Operating margin-22.75%
Return on assets-7.54%
Return on equity-9.59%
Return on investment-8.33%
More ▼

Cash flow in DKKView more

In 2023, cash reserves at Gubra A/S fell by 18.53m. Cash Flow from Financing totalled 382.79m or 186.72% of revenues. In addition the company used 49.42m for operations while cash used for investing totalled 351.39m.
Cash flow per share-2.11
Price/Cash flow per share--
Book value per share28.44
Tangible book value per share27.60
More ▼

Balance sheet in DKKView more

Gubra A/S has a Debt to Total Capital ratio of 16.47%, a higher figure than the previous year's 13.14%.
Current ratio7.24
Quick ratio--
Total debt/total equity0.1972
Total debt/total capital0.1647
More ▼

Growth rates in DKK

Year on year, growth in earnings per share excluding extraordinary items dropped -1,213.33%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-364.56
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.